a2020, notwithstanding the four other drugs Alexion is developing, how much would you have paid for Lipitor before it hit 16 billion in annual sales and $141 billion in sales to date (before going generic)?
They are not interested in Alexion just for Soliris. They are also looking at their pipeline as well. We already know that Roche has approached ALXN already and were "rebuffed" .... Now I am assuming that Roche and the people running it are not exactly "out of their mind". I personally think that holding ALXN until the dust settles will reward those who are willing to unload when the next spike comes up. At one point or another, the bid price will be made public and that by itself will move the stock up to be closer to whatever that price is.